BioLineRx Ltd.

Major Shareholding Notification • Feb 16, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. ) 1

BioLineRx Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.10 per share

(Title of Class of Securities)

09071M205

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSON
	Biotechnology Value Fund, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES	5	SOLE VOTING POWER
BENEFICIALLY		0 shares
OWNED BY EACH	6	SHARED VOTING POWER
REPORTING		13,999,725 (1)
PERSON WITH	7	SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
		13,999,725 (1)
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	13,999,725 (1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	7.8% (1)
12	TYPE OF REPORTING PERSON
	PN

(1) Represents 933,315 American Depositary Shares ("ADS") (each ADS represents 15 Ordinary Shares (as defined below)), including (i) 95,450 ADSs issuable upon the exercise of certain Series A Warrants (as defined below) and (ii) 95,450 ADSs issuable upon the exercise of certain Series B Warrants (as defined below).

1	NAME OF REPORTING PERSON
	BVF I GP LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES	5	SOLE VOTING POWER
BENEFICIALLY		0 shares
OWNED BY	6	SHARED VOTING POWER
EACH
REPORTING PERSON WITH	7	13,999,725 (1) SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
		13,999,725 (1)
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	13,999,725 (1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	7.8% (1)
12	TYPE OF REPORTING PERSON
	OO

(1) Represents 933,315 ADSs (each ADS represents 15 Ordinary Shares) including (i) 95,450 ADSs issuable upon the exercise of certain Series A Warrants and (ii) 95,450 ADSs issuable upon the exercise of certain Series B Warrants.

1	NAME OF REPORTING PERSON
		Biotechnology Value Fund II, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF SHARES	5	SOLE VOTING POWER
BENEFICIALLY		0 shares
OWNED BY EACH	6	SHARED VOTING POWER
REPORTING		10,541,415 (1)
PERSON WITH	7	SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
		10,541,415 (1)
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	10,541,415 (1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.9% (1)
12	TYPE OF REPORTING PERSON
	PN

(1) Represents 702,761 ADSs (each ADS represents 15 Ordinary Shares), including (i) 59,536 ADSs issuable upon the exercise of certain Series A Warrants and (ii) 59,536 ADSs issuable upon the exercise of certain Series B Warrants.

1	NAME OF REPORTING PERSON
	BVF II GP LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF	5	SOLE VOTING POWER
SHARES
BENEFICIALLY		0 shares
OWNED BY EACH	6	SHARED VOTING POWER
REPORTING		10,541,415 (1)
PERSON WITH	7	SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
		10,541,415 (1)
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10	10,541,415 (1)	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
12	5.9% (1) TYPE OF REPORTING PERSON
	OO

(1) Represents 702,761 ADSs (each ADS represents 15 Ordinary Shares), including (i) 59,536 ADSs issuable upon the exercise of certain Series A Warrants and (ii) 59,536 ADSs issuable upon the exercise of certain Series B Warrants.

1	NAME OF REPORTING PERSON
	Biotechnology Value Trading Fund OS LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands
NUMBER OF	5	SOLE VOTING POWER
SHARES BENEFICIALLY		0 shares
OWNED BY	6	SHARED VOTING POWER
EACH REPORTING		2,663,550 (1)
PERSON WITH	7	SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
		2,663,550 (1)
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	2,663,550 (1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	1.5% (1)
12	TYPE OF REPORTING PERSON
	PN

(1) Represents 177,570 ADSs (each ADS represents 15 Ordinary Shares), including (i) 16,520 ADSs issuable upon the exercise of certain Series A Warrants and (ii) 16,520 ADSs issuable upon the exercise of certain Series B Warrants.

1	NAME OF REPORTING PERSON
	BVF Partners OS Ltd.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION
	Cayman Islands
NUMBER OF	5	SOLE VOTING POWER
SHARES
BENEFICIALLY		0 shares
OWNED BY	6	SHARED VOTING POWER
EACH
REPORTING PERSON WITH	7	2,663,550 (1) SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
		2,663,550 (1)
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	2,663,550 (1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	1.5% (1)
12	TYPE OF REPORTING PERSON
	CO

(1) Represents 177,570 ADSs (each ADS represents 15 Ordinary Shares), including (i) 16,520 ADSs issuable upon the exercise of certain Series A Warrants and (ii) 16,520 ADSs issuable upon the exercise of certain Series B Warrants.

1	NAME OF REPORTING PERSON
	BVF GP HOLDINGS LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
NUMBER OF	Delaware 5	SOLE VOTING POWER
SHARES
BENEFICIALLY		0 shares
OWNED BY	6	SHARED VOTING POWER
EACH
REPORTING PERSON WITH	7	24,541,140 (1) SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
9		24,541,140 (1) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	24,541,140 (1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	13.5% (1)
12	TYPE OF REPORTING PERSON
	OO

(1) Represents 1,636,076 ADSs (each ADS represents 15 Ordinary Shares), including (i) 154,986 ADSs issuable upon the exercise of certain Series A Warrants and (ii) 154,986 ADSs issuable upon the exercise of certain Series B Warrants.

1	NAME OF REPORTING PERSON
	BVF Partners L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF	5	SOLE VOTING POWER
SHARES BENEFICIALLY		0 shares
OWNED BY	6	SHARED VOTING POWER
EACH REPORTING		31,942,380 (1)
PERSON WITH	7	SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
		31,942,380 (1)
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	31,942,380 (1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	17.5% (1)
12	TYPE OF REPORTING PERSON
	PN, IA

(1) Represents 2,129,492 ADSs (each ADS represents 15 Ordinary Shares), including (i) 198,228 ADSs issuable upon the exercise of certain Series A Warrants (as defined below) and (ii) 198,228 ADSs issuable upon the exercise of certain Series B Warrants (as defined below).

1	NAME OF REPORTING PERSON
	BVF Inc.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	Delaware
NUMBER OF	5	SOLE VOTING POWER
SHARES BENEFICIALLY		0 shares
OWNED BY	6	SHARED VOTING POWER
EACH REPORTING		31,942,380 (1)
PERSON WITH	7	SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
		31,942,380 (1)
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	31,942,380 (1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	17.5% (1)
12	TYPE OF REPORTING PERSON
	CO

(1) Represents 2,129,492 ADSs (each ADS represents 15 Ordinary Shares), including (i) 198,228 ADSs issuable upon the exercise of certain Series A Warrants (as defined below) and (ii) 198,228 ADSs issuable upon the exercise of certain Series B Warrants (as defined below).

1	NAME OF REPORTING PERSON
	Mark N. Lampert
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
			(b)
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States
NUMBER OF SHARES	5	SOLE VOTING POWER
BENEFICIALLY		0 shares
OWNED BY EACH	6	SHARED VOTING POWER
REPORTING		31,942,380 (1)
PERSON WITH	7	SOLE DISPOSITIVE POWER
		0 shares
	8	SHARED DISPOSITIVE POWER
		31,942,380 (1)
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	31,942,380 (1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	17.5% (1)
12	TYPE OF REPORTING PERSON
	IN

(1) Represents 2,129,492 ADSs (each ADS represents 15 Ordinary Shares), including (i) 198,228 ADSs issuable upon the exercise of certain Series A Warrants (as defined below) and (ii) 198,228 ADSs issuable upon the exercise of certain Series B Warrants (as defined below).

CUSIP No. 09071M205

Item 1(a).	Name of Issuer:
	BioLineRx Ltd., an Israeli corporation (the "Issuer").
Item 1(b).	Address of Issuer's Principal Executive Offices:
	2 HaMa'ayan Street Modi'in 7177871 Israel
Item 2(a). Item 2(b). Item 2(c).	Name of Person Filing Address of Principal Business Office or, if None, Residence Citizenship
	Biotechnology Value Fund, L.P. ("BVF") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware
	BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware
	Biotechnology Value Fund II, L.P. ("BVF2") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware
	BVF II GP LLC ("BVF2 GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware
	Biotechnology Value Trading Fund OS LP ("Trading Fund OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands
	BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands
	BVF GP Holdings LLC ("BVF GPH") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware
	BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

	BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware
	Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States
			Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
Item 2(d).	Title of Class of Securities:
			Ordinary Shares, par value NIS 0.10 per share (the "Ordinary Shares").
Item 2(e).	CUSIP Number:
	09071M205
Item 3.			If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
		/x/	Not applicable.
	(a)	/ /	Broker or dealer registered under Section 15 of the Exchange Act.
	(b)	/ /	Bank as defined in Section 3(a)(6) of the Exchange Act.
	(c)	/ /	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
	(d)	/ /	Investment company registered under Section 8 of the Investment Company Act.
	(e)	/ /	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
	(f)	/ /	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
	(g)	/ /	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
	(h)	/ /	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
	(i)	/ /	A church plan that is excluded from the definition of an investment company under Section 3(c) (14) of the Investment Company Act.
	(j)	/ /	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
	(k)	/ /	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

CUSIP No. 09071M205

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on December 31, 2019, The Reporting Persons held 198,228 Series A Warrants exercisable for an aggregate of 198,228 ADSs (the "Series A Warrants"). The Series A Warrants have an exercise price of \$2.00 per Ordinary Share. The Series A Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), more than 24.99% of the Ordinary Shares issued and outstanding (the "Series A Warrants Blocker"). In providing beneficial ownership described herein, the Reporting Persons have assumed the Series A Warrants owned by each of BVF, BVF2 and Trading Fund OS and held in the Partners managed accounts (the "Partners Managed Accounts") would be fully exercised.

As of the close of business on December 31, 2019, the Reporting Persons held 198,228 Series B Warrants exercisable for an aggregate of 198,228 ADSs (the "Series B Warrants"). The Series B Warrants have an exercise price of \$4.00 per Ordinary Share. The Series B Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 24.99% of the Ordinary Shares issued and outstanding (the "Series B Warrants Blocker"). In providing beneficial ownership described herein, the Reporting Persons have assumed the Series B Warrants owned by each of BVF, BVF2 and Trading Fund OS and held in the Partners Managed Accounts would be fully exercised.

As of the close of business on December 31, 2019, (i) BVF beneficially owned 13,999,725 Ordinary Shares (represented by 933,315 ADSs, including (a) 95,450 ADSs issuable upon the exercise of Series A Warrants and (b) 95,450 ADSs issuable upon the exercise of Series B Warrants), (ii) BVF2 beneficially owned 10,541,415 Ordinary Shares (represented by 702,761 ADSs, including (a) 59,536 ADSs issuable upon the exercise of Series A Warrants and (b) 59,536 ADSs issuable upon the exercise of Series B Warrants), and (iii) Trading Fund OS beneficially owned 2,663,550 Ordinary Shares (represented by 177,570 ADSs, including (a) 16,520 ADSs issuable upon the exercise of Series A Warrants and (b) 16,520 ADSs issuable upon the exercise of Series B Warrants).

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 13,999,725 Ordinary Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 10,541,415 Ordinary Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 2,663,550 Ordinary Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 24,541,140 Ordinary Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 31,942,380 Ordinary Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, including 4,737,690 Ordinary Shares held in the Partners Managed Accounts (represented by 315,846 ADSs, including (a) 26,722 ADSs issuable upon the exercise of Series A Warrants and (b) 26,722 ADSs issuable upon the exercise of Series B Warrants).

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 31,942,380 Ordinary Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 31,942,380 Ordinary Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Ordinary Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Ordinary Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Ordinary Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Ordinary Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Ordinary Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Ordinary Shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on a denominator which is the sum of: (i) 177,008,993 Ordinary Shares outstanding, which is the total number of Ordinary Shares outstanding as disclosed in the Issuer's Proxy Statement, which was included as Exhibit 1 to the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on January 30, 2020, (ii) certain or all of the 2,973,420 Ordinary Shares (represented by 198,228 ADSs) underlying the Series A Warrants, as applicable, and (iii) certain or all of the 2,973,420 Ordinary Shares (represented by 198,228 ADSs) underlying the Series B Warrants, as applicable.

As of the close of business on December 31, 2019, (i) BVF beneficially owned approximately 7.8% of the outstanding Ordinary Shares, (ii) BVF2 beneficially owned approximately 5.9% of the outstanding Ordinary Shares, (iii) Trading Fund OS beneficially owned approximately 1.5% of the outstanding Ordinary Shares, (iv) BVF GP may be deemed to beneficially own approximately 7.8% of the outstanding Ordinary Shares, (v) BVF2 GP may be deemed to beneficially own approximately 5.9% of the outstanding Ordinary Shares, (vi) Partners OS may be deemed to beneficially own approximately 1.5% of the outstanding Ordinary Shares, (vii) BVF GPH may be deemed to beneficially own approximately 13.5% of the outstanding Ordinary Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 17.5% of the outstanding Ordinary Shares (approximately 2.7% of the outstanding Ordinary Shares are held in the Partners Managed Accounts).

	(c)	Number of shares as to which such person has:
	(i)	Sole power to vote or to direct the vote
		See Cover Pages Items 5-9.
	(ii)	Shared power to vote or to direct the vote
		See Cover Pages Items 5-9.
	(iii)	Sole power to dispose or to direct the disposition of
		See Cover Pages Items 5-9.
	(iv)	Shared power to dispose or to direct the disposition of
		See Cover Pages Items 5-9.
Item 5.		Ownership of Five Percent or Less of a Class.
		Not Applicable.
Item 6.		Ownership of More than Five Percent on Behalf of Another Person.
		BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Ordinary Shares beneficially owned by BVF. BVF2 GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Ordinary Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Ordinary Shares beneficially owned by Trading Fund OS and the Partners Managed Accounts.
Item 7.		Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
		Not Applicable.
Item 8.		Identification and Classification of Members of the Group.
		See Exhibit 99.1.
Item 9.		Notice of Dissolution of Group.
		Not Applicable.
Item 10.		Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2020

• By: BVF I GP LLC., its general partner By: BVF Partners L.P., its investment manager
• By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert

BVF I GP LLC

By: /s/ Mark N. Lampert Mark N. Lampert By: /s/ Mark N. Lampert Chief Executive Officer Mark Lampert

BIOTECHNOLOGY VALUE FUND II, L.P.

• By: BVF II GP LLC its general partner
• By: /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert

BVF II GP LLC

By: /s/ Mark N. Lampert Chief Executive Officer Mark Lampert

BVF PARTNERS OS LTD.

• By: BVF Partners L.P., its sole member MARK N. LAMPERT
• By: BVF Inc., its general partner
• By: /s/ Mark N. Lampert Mark N. Lampert President

BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP

• By: BVF Inc., its general partner
• Chief Executive Officer Mark Lampert President

BVF GP HOLDINGS LLC

Chief Executive Officer

BVF PARTNERS L.P.

• By: BVF Inc., its general partner
• Mark N. Lampert By: /s/ Mark N. Lampert President

BVF INC.

Mark N. Lampert By: /s/ Mark N. Lampert

President

/s/ Mark N. Lampert